U.S. Water Utilities Stock News

NasdaqGS:HIMX
NasdaqGS:HIMXSemiconductor

Is It Too Late To Reassess Himax Technologies (HIMX) After Its Surging Share Price?

If you are wondering whether Himax Technologies at US$16.03 is priced attractively or already baking in a lot of optimism, it helps to step back and look at what the recent data is actually saying about value. The stock has posted returns of 36.4% over 7 days, 83.6% over 30 days, 87.9% year to date, 120.2% over 1 year, 180.8% over 3 years, and 102.0% over 5 years, which can shift how the market views both its potential and its risks. These moves have kept Himax Technologies on the radar of...
NasdaqGS:EMBC
NasdaqGS:EMBCMedical Equipment

Embecta (EMBC) Is Down 60.7% After Dividend Cut And Buyback Shift - What's Changed

In early May 2026, Embecta Corp. reported a year-over-year drop in quarterly sales to US$221.8 million and swung from a net income of US$23.5 million to a net loss of US$4.1 million, while also slashing its quarterly dividend to US$0.01 per share and authorizing a three-year, US$100 million share repurchase program. The combination of weaker Q2 results, lowered full-year guidance, a sharply reduced dividend, and the planned Owen Mumford acquisition highlights how Embecta is reshaping its...
NasdaqGS:CRTO
NasdaqGS:CRTOMedia

Criteo (CRTO) Is Down 13.1% After Weak Q1 2026 Results And Redomiciliation Plan - What's Changed

Criteo S.A. has reported past first-quarter 2026 results showing sales of US$424.64 million versus US$451.43 million a year earlier, with net income falling to US$7.82 million from US$37.93 million and diluted EPS from continuing operations declining to US$0.15 from US$0.66. Alongside weaker Retail Media performance and lower profitability, Criteo is proceeding with a legal redomiciliation to Luxembourg aimed at easing buyback constraints and improving access to U.S. capital markets. We’ll...
NasdaqGS:DASH
NasdaqGS:DASHHospitality

DoorDash (DASH) Q1 Net Margin At 6.3% Tests Bullish Profitability Narrative

Q1 2026 results set the scene DoorDash (DASH) opened 2026 with Q1 revenue of US$4.0 billion and basic EPS of US$0.42, setting a clear benchmark for how the business is currently converting its scale into per share profitability. The company has seen quarterly revenue move from US$2.9 billion in Q4 2024 to US$3.0 billion in Q1 2025 and then to US$4.0 billion in Q1 2026, while basic EPS over the same period went from US$0.34 to US$0.46 and then US$0.42, giving investors a clean view of how...
NYSE:LNG
NYSE:LNGOil and Gas

Cheniere Energy Q1 Loss Of US$3.5b Tests Bullish Contract Stability Narrative

Cheniere Energy (LNG) opened Q1 2026 with revenue of US$5.9b and a basic EPS loss of US$16.64, compared with Q1 2025 revenue of US$5.4b and basic EPS of US$1.57. Trailing twelve month EPS sits at US$6.75 on revenue of US$19.9b. Over the last few quarters, revenue has moved from US$4.5b in Q4 2024 to US$5.0b in Q4 2025 and EPS has ranged from US$4.35 to US$10.72 before this latest quarterly loss. This leaves investors weighing a fuller year of positive EPS against a tough quarter for margins...
NasdaqGS:ENTG
NasdaqGS:ENTGSemiconductor

How Investors Are Reacting To Entegris (ENTG) Strong Q1 Results, Upbeat Guidance, Expanded Credit Line, New CFO

Entegris, Inc. recently reported first-quarter 2026 results showing higher sales and net income year on year, issued stronger earnings guidance for the next two quarters, amended its revolving credit facility to US$750.00 million through 2031, and appointed industry veteran Sukhi Nagesh as CFO effective May 18, 2026. Together, these updates highlight Entegris’ focus on reinforcing its balance sheet, tightening operations, and deepening semiconductor-sector expertise in its finance leadership...
NasdaqGS:CLOV
NasdaqGS:CLOVHealthcare

Clover Health (CLOV) Quarterly Profit Challenges Longstanding Bearish Loss Narratives

Clover Health Investments (CLOV) opened Q1 2026 with revenue of US$749.2 million and basic EPS of US$0.05, alongside net income excluding extra items of US$27.3 million, giving investors a clean read on the core business. Over the last five reported quarters, revenue has moved from US$336.9 million in Q4 2024 to US$749.2 million in Q1 2026, while quarterly basic EPS has shifted from a loss of US$0.04 to a profit of US$0.05. This sets up this update as a key check on whether those improving...
NYSE:COR
NYSE:CORHealthcare

Cencora (COR) Q2 2026 EPS Surge Tests Bullish Earnings Growth Narratives

Cencora (COR) has put up a busy Q2 2026, with revenue of about US$78.4b, basic EPS of US$8.44 and net income of US$1,641.3m setting the tone for this earnings season update. Over the past six reported quarters, revenue has moved between roughly US$75.5b and US$86.0b while quarterly EPS has ranged from a loss of US$1.75 to a high of US$8.44. This gives investors a clear view of how the earnings line has tracked alongside a very large top line. Taken together with trailing twelve month EPS of...
NYSE:GOLD
NYSE:GOLDRetail Distributors

Gold.com (GOLD) Q3 Earnings Surge While Ultra Thin Margins Challenge Bullish Narratives

Gold.com (GOLD) just posted Q3 2026 results with revenue of about US$10.4b and net income of US$59.5m, equal to EPS of US$2.17, against a backdrop of 112.2% earnings growth over the past year and low net margins of around 0.3%. The company has seen quarterly revenue move from US$3.0b in Q3 2025 to US$10.4b in Q3 2026, while EPS shifted from a loss of US$0.36 to a profit of US$2.17 over the same periods, highlighting a combination of earnings momentum and thin margins for investors. See our...
NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Reassessing Viridian Therapeutics (VRDN) After Volatile Share Price Swings

If you are wondering whether Viridian Therapeutics at around US$16.97 is priced for opportunity or risk, the key question is what that tag really says about the business. The stock has recently shown sharp moves, with returns of 25.9% over 7 days and 21.6% over 30 days, while year to date it is down 44.7% and up 32.8% over the past year. This mix of recent gains and earlier weakness has put valuation back in focus as investors reassess what they are willing to pay for Viridian Therapeutics...
NYSE:LCII
NYSE:LCIIAuto Components

LCI Industries Faces Standalone Future After Patrick Merger Talks End

LCI Industries and Patrick Industries have ended merger of equals talks, halting plans to combine their RV supply operations. The termination marks a key corporate event that could affect how both businesses position themselves in the recreational vehicle supply sector. Investors now have to assess NYSE:LCII on a standalone basis, without potential merger related changes to scale or product breadth. LCI Industries, ticker NYSE:LCII, recently closed at $116.43, with the stock showing a 41.7%...